New longer-lasting factor VIII for severe hemophilia A (on-demand use)
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial tests a new longer-lasting factor VIII medicine (FRSW107) for on-demand treatment of bleeding episodes. It is for males with severe hemophilia A who have been previously treated at least 150 times.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are male, aged 12 to 65.
- You have severe hemophilia A, meaning your factor VIII level is below 1%.
- You have been treated with factor VIII products at least 150 times before (about 150 exposure days).
- You do not currently have or have not had a factor VIII inhibitor (antibodies that interfere with treatment).
- Your liver, kidneys, and blood counts are within safe limits (checked by screening tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new long-acting factor VIII treatment (FRSW107) for people with severe hemophilia A. It aims to prevent bleeding episodes with fewer injections, and you must have already used factor VIII treatments many times before.
This trial tests a new form of factor VIII that lasts longer in the body, so you may need fewer infusions. It is for men with severe hemophilia A who have already used factor VIII products for at least 150 days.
This trial tests a new long-acting factor VIII treatment (FRSW107) for boys under 12 with severe hemophilia A. It aims to see if the drug is safe and effective at preventing or treating bleeding episodes.
This study tests a new medicine called SCT800 for boys with severe hemophilia A who have never been treated with factor VIII before. The goal is to see if it works safely to prevent bleeding.
This trial is testing a new injection called SR604 in people with congenital factor VII deficiency, a rare bleeding disorder. The study will check if the drug is safe and effective at preventing or treating bleeding episodes.
This study tests whether KN057, a new preventive medicine, is safe for males with hemophilia A or B. It aims to help prevent bleeding episodes without causing unwanted blood clots.
Hear when a new Severe Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.